Law firms Skadden, Freshfields and Davis Polk take the lead as blockbuster Pfizer/AstraZeneca deal gears up again Jaishree Kalia · 28 April 2014 · 2 min read Corporate and M&A Davis Polk Freshfields Skadden, Arps, Slate, Meagher & Flom Skadden, Arps, Slate, Meagher & Flom, Freshfields Bruckhaus Deringer and Davis Polk & Wardwell have all landed lead roles advising Pfizer and AstraZeneca as talks over a potential $100bn merger resurface.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryAnglo American and Teck name top lawyer for $69bn mining mega-mergerIn-HouseTheresa Hargreaves31 Jul 2026Freshfields and Slaughters set to share £40m-plus fees on EQT-Intertek dealLaw firmsTom Cox30 Jul 2026Freshfields hires ex-Cravath dealmaker in New YorkLaw firmsWill Lewallen28 Jul 2026HSF Kramer and Jones Day advise as Sainsbury’s offloads Argos for £120mLaw firmsTheresa Hargreaves31 Jul 2026US quartet lead on Grant Thornton’s landmark $5bn CBIZ acquisitionLaw firmsTheresa Hargreaves30 Jul 2026Revolving doors: Simpson Thacher, Latham, Sidley lead New Year London movesLaw firmsAnna Huntley9 Jan 2025‘Seize every opportunity’ – Paul Hastings partner Reena Gogna on City law, Suits and poetryLaw firmsAnna Huntley7 Jan 2025Five partners vie to succeed Hoyland as Simmons managing partnerLaw firmsTom Cox7 Jan 2025Former Freshfields senior partner among recipients in New Year Honours ListLaw firmsTom Cox2 Jan 2025